Becton Dickinson Q4 revenue beats estimates on broad-based growth
Overview
U.S. medical technology firm's fiscal Q4 revenue rose 5.4%, beating analyst expectations
Adjusted EPS for fiscal Q4 climbed 27%, beating analyst expectations
Company completed spin-off of Life Sciences business, focusing on core MedTech operations
Outlook
Company sees FY27 GAAP and FXN revenue growth in low single-digit percentage range
Becton Dickinson expects FY27 adjusted diluted EPS of $13.10 to $13.30
Result Drivers
SEGMENT GROWTH - Co reported broad-based revenue growth across Medical Essentials, BioPharma Systems and Interventional segments
PRODUCT LAUNCHES - Co highlighted new launches in pharmacy automation and vascular intervention as contributing to performance
SUPPLY CHAIN PARTNERSHIP - Co cited partnership with U.S. government to expand domestic manufacturing and supply chain resilience
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $5.27 bln | $5.11 bln (12 Analysts) |
Q4 Adjusted EPS | Beat | $4.15 | $4.07 (14 Analysts) |
Q4 EPS | $2.52 |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Becton Dickinson and Co is $205.00, about 2% above its November 4 closing price of $209.19
The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 12 three months ago
Reuters Recommended Reads
Nov 4 - Zimmer Biomet Q3 sales beat estimates, raises FY outlook
Nov 4 - UK's Smith & Nephew misses Q3 revenue estimates, cuts outlook on slower US orthopaedics market
Nov 4 - Edwards Lifesciences Q3 sales beat on TMTT portfolio adoption
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)